Precision Biosensor

Precision Biosensor Stock-Based Compensation

The Stock-Based Compensation (SBC) of Precision Biosensor (335810.KQ) as of Oct 28, 2026 is 116.00 M KRW. In the previous year, Stock-Based Compensation (SBC) was 46.61 M KRW — a change of 148.86% (higher).

Stock-Based Compensation

116.00 MKRW

YoY

148.86%

Last updated:

Stock-Based Compensation (SBC) of Precision Biosensor is 2025 116.00 M KRW. Stock-Based Compensation (SBC) of Precision Biosensor was 2024 46.61 M KRW. It decreases by 148.86% higher compared to the previous year.

The Precision Biosensor Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2020
2.84 M KRW
Jan 1, 2021
73.59 M KRW
Jan 1, 2022
150.33 M KRW
Jan 1, 2023
155.26 M KRW
Jan 1, 2024
46.61 M KRW
Jan 1, 2025
116.00 M KRW
The Precision Biosensor Stock-Based Compensation history
YEARStock-Based CompensationYoY
116.00 MKRW+148.86%
46.61 MKRW-69.98%
155.26 MKRW+3.28%
150.33 MKRW+104.27%
73.59 MKRW+2,494.99%
2.84 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Precision Biosensor Stock analysis

What does Precision Biosensor do? Precision Biosensor Inc. generates revenue through the sale of portable immunoassay diagnostic devices and cartridges. The testers, which are portable devices using colorimetric and time-resolved fluorescence, are sold for on-site diagnosis of acute heart disease, metabolism, and inflammatory diseases. The cartridges, designed for gold absorption and time-resolved fluorescence analysis, are used in diagnostic equipment to check the same conditions. The company targets domestic and overseas markets including Europe, China, the Middle East, and Southeast Asia for its products. The firm's primary customers are healthcare providers and diagnostic laboratories seeking rapid, on-site testing solutions. These segments value the portability and speed of the testers, which enable immediate diagnosis without laboratory processing. The cartridges complement the testers by providing consumable components for consistent diagnostic accuracy across various medical conditions. Precision Biosensor Inc. focuses on markets where demand for point-of-care diagnostics is growing, particularly in regions with expanding healthcare infrastructure. The company's product line addresses acute heart disease, metabolism, and inflammatory diseases, aligning with global health priorities. Sales in Europe, China, the Middle East, and Southeast Asia reflect the company's strategy to serve both developed and emerging healthcare systems. Precision Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precision Biosensor stock

Stock-Based Compensation (SBC) of Precision Biosensor is 116.00 M KRW in 2025.

Stock-Based Compensation (SBC) of Precision Biosensor changed from 46.61 M KRW to 116.00 M KRW, representing a 148.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Precision Biosensor since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Precision Biosensor historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Precision Biosensor

All Key Metrics — Precision Biosensor